The high 91% implied probability for no new COVID variant of concern before 2027 reflects sustained low-risk assessments from WHO and ECDC surveillance through July 2026. Circulating lineages such as NB.1.8.1, XFG, and BA.3.2 (the “Cicada” variant with over 70 spike mutations) remain classified only as variants under monitoring, with no evidence of increased severity, transmissibility, or immune escape sufficient for variant-of-concern status. Recent genomic data show these sublineages evolving gradually within the Omicron family, while overall case rates and hospitalizations stay low. Vaccine updates for the 2026-2027 formula target existing JN.1-lineage strains, underscoring continuity rather than abrupt shifts. With just five months until 2027 and no signals of rapid escalation in the past several months, traders see limited scope for a qualifying designation in the near term.
Resumen experimental generado por IA con datos de Polymarket. Esto no es asesoramiento de trading y no influye en cómo se resuelve este mercado. · ActualizadoSí
$243,750 Vol.
$243,750 Vol.
Sí
$243,750 Vol.
$243,750 Vol.
The CDC's variant classification scheme can be found here: https://stacks.cdc.gov/view/cdc/107682.
The resolution source for this market will be official information from the CDC.
Mercado abierto: Dec 1, 2025, 4:49 PM ET
Resolver
0x65070BE91...The CDC's variant classification scheme can be found here: https://stacks.cdc.gov/view/cdc/107682.
The resolution source for this market will be official information from the CDC.
Resolver
0x65070BE91...The high 91% implied probability for no new COVID variant of concern before 2027 reflects sustained low-risk assessments from WHO and ECDC surveillance through July 2026. Circulating lineages such as NB.1.8.1, XFG, and BA.3.2 (the “Cicada” variant with over 70 spike mutations) remain classified only as variants under monitoring, with no evidence of increased severity, transmissibility, or immune escape sufficient for variant-of-concern status. Recent genomic data show these sublineages evolving gradually within the Omicron family, while overall case rates and hospitalizations stay low. Vaccine updates for the 2026-2027 formula target existing JN.1-lineage strains, underscoring continuity rather than abrupt shifts. With just five months until 2027 and no signals of rapid escalation in the past several months, traders see limited scope for a qualifying designation in the near term.
Resumen experimental generado por IA con datos de Polymarket. Esto no es asesoramiento de trading y no influye en cómo se resuelve este mercado. · Actualizado
Cuidado con los enlaces externos.
Cuidado con los enlaces externos.
Preguntas frecuentes